Table 4.
IC50 ratio | % Apoptotic cells | ||
---|---|---|---|
IC50 of P. kesiya | IC50 of Melphalan | U937 | HepG2 |
0 | 1 | 43.1 ± 16.3 | 53.0 ± 6.1 |
1 | 0 | 42.5 ± 4.8b | 39.7 ± 2.6a |
1 | 1 | 100a | 100a |
0.1 | 1 | 77.0 ± 1.9a | 66.7 ± 3.1a |
0.2 | 1 | 100a | 74.9 ± 12.3a |
0.5 | 1 | 100a | 92.8 ± 1.3a |
1.5 | 1 | 100a | 98.3 ± 3.0a |
2 | 1 | 100a | 100a |
1 | 0.05 | 38.6 ± 6.1a | 62.4 ± 3.2a |
1 | 0.1 | 48.4 ± 3.8a | 87.9 ± 3.3a |
1 | 0.2 | 61.3 ± 3.3a | 90.3 ± 6.0a |
1 | 0.5 | 100a | 100a |
1 | 1.5 | 100a | 100a |
1 | 2 | 100a | 100a |
One-way ANOVA of percentage apoptotic cells compared with single treatment by melphalan at 1 × IC50 in cancer cells
aSignificant difference (P < 0.001)
bNon-significant difference (P ≥ 0.001)